Private company

Tracon Pharmaceuticals, Inc.

Biological products company1

In its 2024 annual report the company says: “We are a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing our cost efficient, contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize innovative products in the United States.”3 It is headquartered in San Diego, California.1

Last updated Oct 20, 2026.

Overview

  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersSan Diego, California1
  • Business address4350 La Jolla Village Drive, Suite 800, San Diego, Ca 921222
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

We are a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing our cost efficient, contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize innovative products in the United States.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-77.0%Operating margin4
-29.8%Net margin4

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development100¢$12.3M

Out of $12.0M in revenue.4 The company lost money this year.

Where each dollar of operating cash went, fiscal 2023

  • Kept or used elsewhere100¢$3.7M

Out of $3.7M of cash from operations.4

Financial statements

Revenue56784$12.0M in 2023+38% since 2017
0$5.0M$10.0M$15.0M2017: $8.8M$8.8M20172018: $3.0M$3.0M2018−66%2019: $0$020192020: $0$020202021: $346.0K$346.0K20212022: $0$020222023: $12.0M$12.0M2023
Operating income56784-$9.3M in 2023−49% since 2017
-$40.0M-$30.0M-$20.0M-$10.0M02017: -$18.2M-$18.2M20172018: -$34.7M-$34.7M2018+91%2019: -$22.3M-$22.3M2019−36%2020: -$16.2M-$16.2M2020−27%2021: -$28.3M-$28.3M2021+75%2022: -$27.9M-$27.9M2022−2%2023: -$9.3M-$9.3M2023−67%
Net income56784-$3.6M in 2023−81% since 2017
-$40.0M-$30.0M-$20.0M-$10.0M02017: -$19.1M-$19.1M20172018: -$35.0M-$35.0M2018+83%2019: -$22.7M-$22.7M2019−35%2020: -$16.8M-$16.8M2020−26%2021: -$28.7M-$28.7M2021+71%2022: -$29.1M-$29.1M2022+2%2023: -$3.6M-$3.6M2023−88%
Fiscal year2017201820192020202120222023
Revenue$8.8M5$3.0M6$07$08$346.0K4$08$12.0M4
Research and development$19.4M5$30.5M6$14.5M7$8.2M8$11.1M4$13.9M4$12.3M4
Operating expenses$28.7M4$27.9M4$21.3M4
Operating income-$18.2M5-$34.7M6-$22.3M7-$16.2M8-$28.3M4-$27.9M4-$9.3M4
Income tax$05$06$07$08$04$04$04
Net income-$19.1M5-$35.0M6-$22.7M7-$16.8M8-$28.7M4-$29.1M4-$3.6M4
Earnings per share-$1.878-$1.664-$1.394-$0.114
Earnings per share (diluted)-$1.878-$1.664-$1.394-$0.114
Shares (weighted, basic)17.3M shares420.9M shares432.7M shares4
Shares (weighted, diluted)17.3M shares420.9M shares432.7M shares4

Compare Tracon Pharmaceuticals, Inc. with another company

Corporate structure

Tracon Pharmaceuticals, Inc. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Tracon Pharmaceuticals, Inc.

  • Ikarian Capital, LLC Filed SC 13G/A on Tracon Pharmaceuticals, Inc., latest Nov 14, 2024 (4 filings since Feb 14, 2022)
  • Wayne Aaronson Filed SC 13G/A on Tracon Pharmaceuticals, Inc., latest Mar 19, 2024 (3 filings since Apr 29, 2022)
  • Lincoln Park Capital Fund, LLC Filed SC 13G/A on Tracon Pharmaceuticals, Inc., latest Feb 14, 2024 (2 filings since Jun 2, 2023)
  • Opaleye Management Inc. Filed SC 13D/A on Tracon Pharmaceuticals, Inc., latest Feb 9, 2024
  • Linden Capital L.P. Filed SC 13G/A on Tracon Pharmaceuticals, Inc., latest Jan 27, 2022
  • Tracon Pharmaceuticals, Inc. San Diego, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Tracon Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$243.0K4 Dec 31, 2023$243.0K4 Dec 31, 20220%
Accumulated depreciation$206.0K4 Dec 31, 2023$192.0K4 Dec 31, 2022+7.3%
Property and equipment, net$37.0K4 Dec 31, 2023$51.0K4 Dec 31, 2022−27.5%
Operating-lease assets (leased space)$905.0K4 Dec 31, 2023$1.1M4 Dec 31, 2022−19.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$8.6M4 Dec 31, 2023$17.4M4 Dec 31, 2022−50.9%
Marketable securities, current$04 Dec 31, 2023$08 Dec 31, 2022
Debt securities available for sale$10.2M8 Dec 31, 2022$5.2M8 Dec 31, 2021+93.4%

Leadership

Who has led Tracon Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Charles Theuer2015–2024

President

  1. Charles Theuer2015–2024

Chief financial officer

  1. Patricia L. Bitar2015–2018

Chief operating officer

  1. Bonne J. Adams2023
20202025
Board members and other officers (15)

Former names

  • Tracon Pharmaceuticals IncMar 22, 2007 to Sep 15, 20142

Timeline

  1. Oct 11, 20248-K Unregistered sale of shares; Bylaws or fiscal year changed; Shareholder vote29
  2. Jul 30, 20248-K Exit or restructuring costs; Executive or director change30
  3. Jul 16, 20248-K Listing notice or transfer31
  4. Jul 1, 20248-K Other events32
  5. Jun 21, 20248-K Executive or director change33
  6. Jun 12, 20248-K Listing notice or transfer34
  7. May 14, 20248-K Results of operations35
  8. May 13, 20248-K Executive or director change36
  9. Apr 12, 20248-K Results of operations; Other events37
  10. Apr 10, 20248-K Other events38
  11. Apr 8, 20248-K Change to shareholders' rights; Bylaws or fiscal year changed39
  12. Apr 3, 20248-K Other events40
  13. Jan 29, 2015New chief executive Charles Theuer becomes CEO12

Calendar

When it reported results

  1. May 14, 2024Reported quarterly or annual results35
  2. Apr 12, 2024Reported quarterly or annual results37
  3. Mar 5, 2024Reported quarterly or annual results41
  4. Nov 9, 2023Reported quarterly or annual results42
  5. Aug 14, 2023Reported quarterly or annual results43
  6. May 10, 2023Reported quarterly or annual results44
  7. Mar 8, 2023Reported quarterly or annual results45
  8. Jan 6, 2023Reported quarterly or annual results46

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

224 filings to the SEC since October 2021: 3 annual reports, 9 quarterly reports, 59 major events, 81 insider forms, 11 large holders, 61 other. The latest 20:

  1. Nov 14, 2024SC 13G/A EDGAR
  2. Nov 7, 202415-12G EDGAR
  3. Nov 1, 2024EFFECT EDGAR
  4. Nov 1, 2024EFFECT EDGAR
  5. Nov 1, 2024EFFECT EDGAR
  6. Nov 1, 2024EFFECT EDGAR
  7. Nov 1, 2024EFFECT EDGAR
  8. Nov 1, 2024EFFECT EDGAR
  9. Nov 1, 2024EFFECT EDGAR
  10. Nov 1, 2024EFFECT EDGAR
  11. Oct 31, 2024RW EDGAR
  12. Oct 31, 2024POS AM EDGAR
  13. Oct 31, 2024POS AM EDGAR
  14. Oct 31, 2024POS AM EDGAR
  15. Oct 31, 2024POS AM EDGAR
  16. Oct 31, 2024POS AM EDGAR
  17. Oct 31, 2024POS AM EDGAR
  18. Oct 31, 2024POS AM EDGAR
  19. Oct 31, 2024POS AM EDGAR
  20. Oct 31, 2024S-8 POS EDGAR

The 224 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

68 open-market trades by officers, directors and large owners since October 2021: 65 buys and 3 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 10, 2023Opaleye Management Inc.10% ownerSale4,764,008$0.29$1.4MForm 4
Apr 27, 2023THEUER CHARLESPRESIDENT AND CEOBuy47,000$0.75$35.2KForm 4
Apr 26, 2023THEUER CHARLESPRESIDENT AND CEOBuy3,999$0.66$2.6KForm 4
Mar 9, 2023Opaleye Management Inc.10% ownerBuy174,508$1.38$240.8KForm 4
Mar 1, 2023THEUER CHARLESPRESIDENT AND CEOBuy4,800$1.52$7.3KForm 4
Feb 28, 2023THEUER CHARLESPRESIDENT AND CEOBuy200$1.52$304Form 4
Jan 18, 2023THEUER CHARLESPRESIDENT AND CEOBuy6,800$1.62$11.0KForm 4
Dec 29, 2022Brown Scott B.CHIEF FINANCIAL OFFICERBuy3,500$1.49$5.2KForm 4
Dec 21, 2022LARUE WILLIAM RDirectorSale120$1.26$151Form 4
Dec 14, 2022Opaleye Management Inc.10% ownerBuy167,500$1.26$210.5KForm 4
Dec 14, 2022THEUER CHARLESPRESIDENT AND CEOBuy23,000$1.29$29.7KForm 4
Dec 6, 2022Opaleye Management Inc.10% ownerSale1,539$1.44$2.2KForm 4
Nov 18, 2022THEUER CHARLESPRESIDENT AND CEOBuy13,900$1.41$19.6KForm 4
Nov 3, 2022THEUER CHARLESPRESIDENT AND CEOBuy9,200$1.52$14.0KForm 4
Nov 2, 2022THEUER CHARLESPRESIDENT AND CEOBuy6,000$1.59$9.5KForm 4
Oct 18, 2022Opaleye Management Inc.10% ownerBuy12,500$1.65$20.6KForm 4
Oct 7, 2022THEUER CHARLESPRESIDENT AND CEOBuy5,000$1.77$8.8KForm 4
Oct 3, 2022THEUER CHARLESPRESIDENT AND CEOBuy5,000$1.67$8.3KForm 4
Sep 29, 2022Opaleye Management Inc.10% ownerBuy9,400$1.74$16.4KForm 4
Sep 27, 2022Opaleye Management Inc.10% ownerBuy1,700$1.69$2.9KForm 4

All 68 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Tracon Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARTracon Pharmaceuticals, Inc.1
  • CIK0001394319
  • Employer ID (EIN)34-20375941
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address4350 La Jolla Village Drive, Suite 800, San Diego, CA 921221
  • Phone858-550-07801
  • Shares outstanding3,407,564 as of Aug 8, 202410
  • Public float$7.6M as of Jun 30, 20234
  • On EDGAR sinceMar 22, 20071
  • Filings733 in all: 4 (244), 8-K (170), 3 (37), 10-Q (29), SC 13G/A (28), EFFECT (19), CORRESP (18), UPLOAD (16)1
    All 43 form types

    424B5 (15), CT ORDER (13), DEF 14A (12), SC 13G (12), DEFA14A (11), S-8 (11), S-8 POS (11), 10-K (10), POS AM (8), PRE 14A (6), S-1 (6), S-3 (6), SC 13D/A (6), 424B3 (5), 4/A (4), D (4), REGDEX/A (4), DRS/A (3), DRSLTR (3), FWP (3), REGDEX (3), D/A (2), S-3/A (2), 10-Q/A (1), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERTNAS (1), DEL AM (1), DRS (1), RW (1), S-1/A (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Mar 5, 2024
    Quarterly report (10-Q) Aug 13, 2024
    Proxy statement (DEF 14A) Aug 30, 2024
    Latest 8-K (8-K) Oct 11, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
    SEC EDGAROther events
  39. 39
  40. 40
    SEC EDGAROther events
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51